Page last updated: 2024-11-05

caramiphen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

caramiphen: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6472
CHEMBL ID61946
CHEBI ID135204
SCHEMBL ID181285
MeSH IDM0045604
PubMed CID67173
CHEMBL ID1598472
SCHEMBL ID1374820
MeSH IDM0045604

Synonyms (87)

Synonym
caramiphen
cyclopentanecarboxylic acid, 1-phenyl-, 2-(diethylamino)ethyl ester
MLS000532799 ,
2-(diethylamino)ethyl 1-phenylcyclopentanecarboxylate hydrochloride
smr000140237
2-(diethylamino)ethyl 1-phenylcyclopentanecarboxylate
77-22-5
parpanit
pentaphen (pharmaceutical)
caramifenio [inn-spanish]
parpanil
caramiphene [inn-french]
einecs 201-013-6
2-diethylaminoethyl 1-phenylcyclopentancarboxylat
1-phenylcyclopentanecarboxylic acid 2-(diethylamino)ethyl ester
caramiphen [inn:ban]
brn 2144901
caramiphenum [inn-latin]
PDSP2_000069
PDSP1_000069
CHEBI:135204
CHEMBL61946 ,
2-diethylaminoethyl 1-phenylcyclopentane-1-carboxylate
diethylaminoethyl 1-phenylcyclopentane-1-carboxylate
AKOS001662910
STK179630
2-dimethylaminoethyl 1-phenylcyclopentane-1-carboxylate
97j7np0xjy ,
caramiphene
caramifenio
unii-97j7np0xjy
caramiphenum
2-(diethylamino)ethyl 1-phenylcyclopentane-1-carboxylate
cyclopentanecarboxylicacid, 1-phenyl-, 2-(diethylamino)ethyl ester
AB00088177-01
caramiphen [vandf]
caramiphen [who-dd]
caramiphen [mi]
caramiphen [inn]
AB00088177-10
SCHEMBL181285
bdbm73402
1-phenyl-cyclopentanecarboxylic acid 2-diethylamino-ethyl ester
1-phenyl-1-cyclopentanecarboxylic acid 2-(diethylamino)ethyl ester;hydrochloride
cid_67173
1-phenylcyclopentanecarboxylic acid 2-(diethylamino)ethyl ester;hydrochloride
OFAIGZWCDGNZGT-UHFFFAOYSA-N
2-(diethylamino)ethyl 1-phenylcyclopentanecarboxylate #
DTXSID0022729
1-(2-diethylaminoethoxycarbonyl)-1-phenylcyclopentane
Q5037673
DB11504
NCGC00167426-02
pentoxyverine impurity b
EN300-23519761
Z252849348
caramiphene hydrochloride
caramiphenium chloride
2-diethylaminoethyl 1-phenylcyclopentane-1-carboxylate hydrochloride
cyclopentanecarboxylic acid, 1-phenyl-, 2-(diethylamino)ethyl ester, hydrochloride
einecs 204-758-5
geigy 2747
1-phenylcyclopentanecarboxylic acid 2-diethylaminoethyl ester hydrochloride
caramiphen hydrochloride
hydrochloride of 1-phenylcyclopentanecarboxylic acid diethylaminoethyl ester
pentaphene hydrochloride
diethylaminoethyl-1-phenylcyclopentane-1-carboxylate hydrochloride
g 2747
125-85-9
unii-4858sn190e
caramiphen hcl
4858sn190e ,
CHEMBL1598472
caramiphen hydrochloride [who-dd]
caramiphen hydrochloride [mi]
SCHEMBL1374820
2-(diethylamino)ethyl 1-phenylcyclopentane-1-carboxylate;hydrochloride
DTXSID70154544
SR-01000212207-1
sr-01000212207
caramiphen hydrochloride, >=98% (hplc)
caramiphenhydrochlorid
caramiphen (hydrochloride)
parpanil hydrochloride;pentaphene hydrochloride
(4-bromophenoxy)aceticacidethylester
Q27259115
cyclopentanecarboxylic acid, 1-phenyl-, 2-(diethylamino)ethyl ester, hydrochloride (1:1)

Research Excerpts

Overview

Caramiphen is a muscarinic antagonist with potent anticonvulsant properties.

ExcerptReferenceRelevance
"Caramiphen is a muscarinic antagonist with potent anticonvulsant properties. "( Neuroprotective efficacy of caramiphen against soman and mechanisms of its action.
Apland, JP; Aroniadou-Anderjaska, V; Braga, MF; Ferrara, TM; Figueiredo, TH; Pidoplichko, V; Qashu, F; Stevens, D, 2011
)
2.11

Toxicity

ExcerptReferenceRelevance
" They were given individually to guinea pigs prior to poisoning with 2 x LD50 soman to test their efficacy against organophosphorus-induced convulsions, brain damage, and lethality."( Prevention of soman neurotoxicity by non-opioid antitussives.
Braitman, DJ; Brennecke, LH; Sparenborg, S, 1990
)
0.28

Compound-Compound Interactions

ExcerptReferenceRelevance
" However, when levetiracetam (LEV; 50mg/kg) was combined with either procyclidine (PCD; 10mg/kg) or caramiphen (CMP; 10mg/kg) complete cessation of seizures was achieved, but the nicotinic antagonist mecamylamine was needed to induce full motor rest in some rats."( Enhanced efficacy of anticonvulsants when combined with levetiracetam in soman-exposed rats.
Aas, P; Enger, S; Jonassen, M; Myhrer, T, 2011
)
0.59
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzenesAny benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (24)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency19.95265.623417.292931.6228AID485281
ATAD5 protein, partialHomo sapiens (human)Potency0.81990.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency25.92900.000811.382244.6684AID686978
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency1.25890.011212.4002100.0000AID1030
glucocerebrosidaseHomo sapiens (human)Potency39.81070.01268.156944.6684AID2101
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency89.12510.035520.977089.1251AID504332
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
DNA polymerase betaHomo sapiens (human)Potency0.15850.022421.010289.1251AID485314
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency31.62280.316212.765731.6228AID881
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency31.62280.00638.235039.8107AID881
Guanine nucleotide-binding protein GHomo sapiens (human)Potency11.22021.995325.532750.1187AID624287
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency14.12541.000010.475628.1838AID1457
TAR DNA-binding protein 43Homo sapiens (human)Potency31.62281.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Ki0.02170.00010.579710.0000AID142719; AID142871
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)Ki0.03200.00011.48339.1400AID142871
Muscarinic acetylcholine receptor M4Rattus norvegicus (Norway rat)Ki0.03200.00010.68688.2600AID142871
Muscarinic acetylcholine receptor M5Rattus norvegicus (Norway rat)Ki0.03200.00010.66618.2600AID142871
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)Ki0.03200.00010.58908.2600AID142871
DRattus norvegicus (Norway rat)Ki1.00000.00010.610010.0000AID61495
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)Ki5.24810.00030.37088.1600AID65638
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki0.50000.00000.437510.0000AID65111
Sigma non-opioid intracellular receptor 1Homo sapiens (human)Ki0.02080.00000.490110.0000AID203702; AID204630
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
short transient receptor potential channel 6 isoform 1Mus musculus (house mouse)EC50 (µMol)15.85000.020020.518970.7900AID2696
ORF73Human gammaherpesvirus 8EC50 (µMol)75.00000.06008.134632.1400AID435023
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (49)

Processvia Protein(s)Taxonomy
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (19)

Processvia Protein(s)Taxonomy
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (27)

Processvia Protein(s)Taxonomy
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (33)

Assay IDTitleYearJournalArticle
AID65638Binding affinity to dopamine transporter (DAT) using [3H]WIN-35428 as a radioligand2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
2D QSAR modeling and preliminary database searching for dopamine transporter inhibitors using genetic algorithm variable selection of Molconn Z descriptors.
AID141829Displacement of [3H]pirenzepine from muscarinic acetylcholine receptor M1 in rat cortex homogenates1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Muscarinic receptor binding profile of para-substituted caramiphen analogues.
AID156838Inhibition of [3H]- (+) - pentazocine binding to PCP receptor obtained from tissue homogenate preparation of fresh whole rat brain minus cerebellum1998Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4
Rigid phencyclidine analogues. Binding to the phencyclidine and sigma 1 receptors.
AID203702The compound was evaluated for affinity at sigma-1 site by inhibition of [3H](+)-pentazocine (PENT) binding in guinea pig brain.1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Novel (4-phenylpiperidinyl)- and (4-phenylpiperazinyl)alkyl-spaced esters of 1-phenylcyclopentanecarboxylic acids as potent sigma-selective compounds.
AID142871Binding affinity was measured against muscarinic (M2) receptor in rat using [3H]QN as radioligand1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Novel (4-phenylpiperidinyl)- and (4-phenylpiperazinyl)alkyl-spaced esters of 1-phenylcyclopentanecarboxylic acids as potent sigma-selective compounds.
AID157452Binding affinity was measured against phencyclidine (PCP) receptor in rat using [3H]-TCP as radioligand at 10 uM1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Novel (4-phenylpiperidinyl)- and (4-phenylpiperazinyl)alkyl-spaced esters of 1-phenylcyclopentanecarboxylic acids as potent sigma-selective compounds.
AID142719Binding affinity was measured against muscarinic (M1) receptor in rat using [3H]pirenzepine as radioligand1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Novel (4-phenylpiperidinyl)- and (4-phenylpiperazinyl)alkyl-spaced esters of 1-phenylcyclopentanecarboxylic acids as potent sigma-selective compounds.
AID61495Binding affinity was measured against dopamine receptor D1 in rat using [3H]SCH-23390 as radioligand1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Novel (4-phenylpiperidinyl)- and (4-phenylpiperazinyl)alkyl-spaced esters of 1-phenylcyclopentanecarboxylic acids as potent sigma-selective compounds.
AID233598Ratio of Ki (M1 receptor) to Ki (M2 receptor) was determined1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Muscarinic receptor binding profile of para-substituted caramiphen analogues.
AID145105Binding affinity was measured against N-methyl-D-aspartate (NMDA) receptor in rat using [3H]CGS-19,755 as radioligand at 10 uM1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Novel (4-phenylpiperidinyl)- and (4-phenylpiperazinyl)alkyl-spaced esters of 1-phenylcyclopentanecarboxylic acids as potent sigma-selective compounds.
AID204630Binding affinity against Sigma receptor type 1 was determined by the displacement of [3H]pentazocine radioligand2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Dual probes for the dopamine transporter and sigma1 receptors: novel piperazinyl alkyl-bis(4'-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents.
AID65111Binding affinity was measured against dopamine (D2) receptor in rat using [3H]spiperone as radioligand1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Novel (4-phenylpiperidinyl)- and (4-phenylpiperazinyl)alkyl-spaced esters of 1-phenylcyclopentanecarboxylic acids as potent sigma-selective compounds.
AID142950Displacement of [3H](-)-quinuclidinyl benzilate(QNB) from muscarinic (M2) receptor in rat heart homogenates1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Muscarinic receptor binding profile of para-substituted caramiphen analogues.
AID232104Ratio of binding affinities for dopamine transporter over sigma-1 receptor2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Dual probes for the dopamine transporter and sigma1 receptors: novel piperazinyl alkyl-bis(4'-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents.
AID744641Inhibition of muscarinic acetylcholine receptor in rat cortex2013Bioorganic & medicinal chemistry, May-01, Volume: 21, Issue:9
Discovery of subtype selective muscarinic receptor antagonists as alternatives to atropine using in silico pharmacophore modeling and virtual screening methods.
AID227699Virtual screen for compounds with anticonvulsant activity2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
AID203833Affinity at sigma-2 site by inhibition of [3H]1,3-di(2-tolyl)guanidine (DTG) binding in guinea pig brain.1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Novel (4-phenylpiperidinyl)- and (4-phenylpiperazinyl)alkyl-spaced esters of 1-phenylcyclopentanecarboxylic acids as potent sigma-selective compounds.
AID65191Binding affinity against dopamine transporter was determined by the displacement of [3H]WIN-35428 radioligand in rat brain2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Dual probes for the dopamine transporter and sigma1 receptors: novel piperazinyl alkyl-bis(4'-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID493017Wombat Data for BeliefDocking2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
2D QSAR modeling and preliminary database searching for dopamine transporter inhibitors using genetic algorithm variable selection of Molconn Z descriptors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (109)

TimeframeStudies, This Drug (%)All Drugs %
pre-199062 (56.88)18.7374
1990's16 (14.68)18.2507
2000's9 (8.26)29.6817
2010's19 (17.43)24.3611
2020's3 (2.75)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.52 (24.57)
Research Supply Index4.71 (2.92)
Research Growth Index4.44 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.92%)5.53%
Trials0 (0.00%)5.53%
Reviews5 (4.59%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other103 (94.50%)84.16%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]